RME Hot Seat: Incorporating Personalized Treatment Into Severe Asthma Management

Access Activity

Overview / Abstract:

Severe, treatment-resistant asthma continues to be an extreme clinical challenge. An estimated 3%–10% of asthma patients have severe asthma, which is characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes.

Fortunately, there have been important developments regarding the clinical management of patients with severe asthma. The discovery that severe asthma comprises multiple phenotypes and distinct endotypes linked to differences in airway remodeling and inflammatory pathophysiology has potentially significant implications for managing this patient population. Also, several new tailored biologic therapies have been approved by the US Food and Drug Administration for use in patients with treatment-resistant severe asthma driven by eosinophilic inflammation, with other new treatments in late-stage development. In 2019, the Global Initiative for Asthma (GINA) updated its stepwise treatment guidelines; these guidelines address the use of biologic therapy for patients with severe asthma.

In this edition of RME Hot Seat, the members of our expert faculty answer challenging clinical questions on existing and emerging personalized treatment, strategies for implementing the most recent clinical guidelines when choosing optimal treatments for patients with severe asthma, the use of biomarkers to guide diagnosis and therapy, differentiating between severe asthma and poorly controlled asthma, and more.


Oct 08, 2020


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME, Respiratory Therapy CE



Credits / Hours

Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Presenters / Authors / Faculty

Michael E. Wechsler, MD, MMSc—Program Chair
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado

Bradley E. Chipps, MD
Medical Director
Capital Allergy & Respiratory Disease Center
Sacramento, California

Flavia C. Hoyte, MD
Associate Professor of Medicine
Allergy/Immunology Fellowship Training Program
Division of Allergy/Immunology
National Jewish Health
University of Colorado
Denver, Colorado

Activity Specialities / Related Topics

Internal Medicine, Family Medicine, Asthma

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Keywords / Search Terms

RedMedEd Asthma, Allergic, Eosinophilic, Neutrophilic. GINA, Phenotype, Endotype, Biomarker, Type 2, Biologic, Anti-IgE, IgE, Anti–IL-5, IL-5, Anti–IL-4, IL-4, personalized, RedMedEd, CME, Free Free CE CME Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.